Cusatuzumab

Cusatuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD70/TNFSF7, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Cusatuzumab is an experimental SIMPLE antibody that targets CD70, which is an immune checkpoint target involving hematological malignancies, a variety of solid tumors, and a variety of autoimmune diseases. Cusatuzumab aims to block CD70 by targeting complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis, and enhancing antibody-dependent cell-mediated cytotoxicity, killing CD70-expressing cancer cells, and recovering Immune monitoring of solid tumors.

Target	CD70/TNFSF7
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Lambda
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1399546-01-0
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on CD70/TNFSF7

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue